Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease.
Platelet activation occurs in the initial phase of venous thrombus formation. To determine if thromboxanes (Tx) are released during this process and if Tx measurements are useful in the diagnosis, urinary immunoreactive TxB2 was measured by a rapid, inexpensive assay in 100 consecutive patients with suspected thromboembolic disease. Urinary iTxB2 was not increased in patients who took aspirin, nor in patients studied several weeks after onset of symptoms. Of the remaining patients, iTxB2 was increased in 11 of 15 with confirmed deep vein thrombosis and in seven of ten with confirmed pulmonary emboli. Of the 54 patients in whom acute thrombosis was excluded, iTxB2 was increased in only four (7 percent). A second study evaluated 25 additional patients with nondiagnostic lung scans who required pulmonary angiography; iTxB2 was increased in seven of ten with positive angiograms and in 0 of 15 with negative angiograms. The three patients with negative iTxB2 and positive angiograms were receiving heparin when studied. These data suggest that, in the absence of aspirin, platelet Tx is released during thrombus formation. In combination with other noninvasive tests, urinary iTxB2 is a useful adjunct to diagnosing acute thromboembolic disease.
D000792:Angiography; D001241:Aspirin; D006801:Humans; D008168:Lung / Q000098:blood supply; D010979:Platelet Function Tests; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000652:urine*; D011863:Radioimmunoassay; D013924:Thrombophlebitis / Q000175:diagnosis / Q000652:urine*; D013929:Thromboxane B2 / Q000652:urine*; D013931:Thromboxanes / Q000652:urine*
D013931:Thromboxanes; D013929:Thromboxane B2; D001241:Aspirin